Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), PD-1 modulators(Programmed cell death protein 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Lymphocytic Leukemia | Phase 1 | JP | 01 Oct 2023 | |
Small Lymphocytic Lymphoma | Phase 1 | JP | 01 Oct 2023 | |
Plaque psoriasis | Phase 1 | MD | 25 Mar 2022 | |
Plaque psoriasis | Phase 1 | RO | 25 Mar 2022 | |
Plaque psoriasis | Phase 1 | GB | 25 Mar 2022 | |
T-cell lymphoma recurrent | Phase 1 | US | 10 Dec 2021 | |
T-cell lymphoma refractory | Phase 1 | US | 10 Dec 2021 | |
Autoimmune Diseases | Phase 1 | JP | - | |
Autoimmune Diseases | Phase 1 | EU | - | |
Psoriasis | Phase 1 | - | - |